Lipids & Metabolic

A recent analysis of last year’s FOURIER trial has found evolocumab, a PCSK9 inhibitor developed to treat hyperlipidemia, can robustly reduce low-density lipoprotein cholesterol (LDL-C) in patients without any major concern for individual-level variability in response.

Questioning older patients about their weight earlier in life could be a low-tech, low-cost way to better predict a person’s future risk of heart disease, according to a study published in the Journal of the American Heart Association.

After years of decline, amputations are increasing among diabetic patients in the U.S., Reuters reported.

As insulin prices in the U.S. continue to surge, lower-income diabetics are struggling to afford a drug their life depends on, researchers report in a JAMA Internal Medicine study published Dec. 3.

The U.S. Department of Agriculture rolled out its final rule on school nutrition standards Dec. 6, allowing schools to ease up on whole grains, permanently serve 1 percent flavored milk and take their time reducing sodium levels in school lunches.

Liraglutide was associated with a 10 percent reduction in major cardiovascular events for patients with type 2 diabetes in a real-world population, offering hope that the cardioprotective benefits observed in randomized trials translate to regular clinical practice.

A little weight lifting can have a big impact on heart health, even in the absence of aerobic endurance training, according to recent research in Medicine & Science in Sports & Exercise.

The authors of a new study in the Annals of Internal Medicine believe too many patients are being recommended statin therapy, and contend that current guidelines don’t fully consider the risks of the popular drugs.

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

There were no adverse events related to atherosclerotic cardiovascular disease during a median 3.7 years of follow-up for 101 patients with familial hypercholesterolemia (FH) but a coronary artery calcium (CAC) score of zero, according to a study published Nov. 14 in JACC: Cardiovascular Imaging.

The FDA is backing a new “qualified health claim” that oils high in oleic acid can help improve cholesterol levels and protect against coronary heart disease, Commissioner Scott Gottlieb, MD, announced Nov. 19.

Diabetics who have transitioned to an employer-mandated, high-deductible insurance plan are significantly more likely to delay healthcare visits for macrovascular symptoms, diagnostic tests and procedures, researchers reported Nov. 20 in the Annals of Internal Medicine.